Literature DB >> 23774674

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

O Kosmider, R Itzykson, V Chesnais, T Lasho, R Laborde, R Knudson, A Gauthier, J Merlevede, L Ades, M Morabito, M Fontenay, A Tefferi, N Droin, E Solary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23774674     DOI： 10.1038/leu.2013.182

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  24 in total

1.  T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation.

Authors:  Sung-Eun Lee; Irene Jo; Woori Jang; Yonggoo Kim; Kyungja Han; Myungshin Kim
Journal:  Ann Lab Med       Date:  2015-04-01       Impact factor: 3.464

Review 2.  Next-generation sequencing-based panel testing for myeloid neoplasms.

Authors:  Frank C Kuo; Fei Dong
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  Colony-stimulating factor-3 receptor, watch out for polymorphisms.

Authors:  C Bilbao-Sieyro; G Santana; L Torres-Miñana; C Rodriguez-Medina; M N Saez; M Perera; Angelina Lemes; S de la Iglesia; T Molero; M T Gomez-Casares
Journal:  Leukemia       Date:  2015-02-24       Impact factor: 11.528

4.  The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Authors:  Julia E Maxson; Samuel B Luty; Jason D MacManiman; Jason C Paik; Jason Gotlib; Peter Greenberg; Swaleh Bahamadi; Samantha L Savage; Melissa L Abel; Christopher A Eide; Marc M Loriaux; Emily A Stevens; Jeffrey W Tyner
Journal:  Clin Cancer Res       Date:  2015-10-16       Impact factor: 12.531

5.  Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

Authors:  T L Lasho; A Mims; M A Elliott; C Finke; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528

Review 6.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 7.  An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.

Authors:  A Tefferi; J Thiele; A M Vannucchi; T Barbui
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

Review 8.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

9.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

10.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.